Serotherapy with thymoglobulin and alemtuzumab differentially influences frequency and function of natural killer cells after allogeneic stem cell transplantation

Bone Marrow Transplantation

Volumn 41, Issue 4, 2008, Pages 377-383

  Penack, O ^a   Fischer, L ^a   Stroux, A ^a   Gentilini, C ^a   Nogai, A ^a   Muessig, A ^a   Rieger, K ^a   Ganepola, S ^a   Herr, W ^b   Meyer, R G ^a   Thiel, E ^a   Uharek, L ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b JOHANNES GUTENBERG UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; FLUDARABINE; GRANULOCYTE COLONY STIMULATING FACTOR; IBRITUMOMAB TIUXETAN; LIPOCORTIN 5; LYSOSOME ASSOCIATED MEMBRANE PROTEIN 1; MELPHALAN; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISOLONE; PROPIDIUM IODIDE; THYMOCYTE ANTIBODY; TREOSULFAN;

ADULT; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER RELAPSE; CELL DEATH; CELLULAR IMMUNITY; CLINICAL ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG HALF LIFE; GRAFT VERSUS HOST REACTION; HEMATOLOGIC MALIGNANCY; HUMAN; HUMAN CELL; IMMUNOREACTIVITY; IMMUNOSUPPRESSIVE TREATMENT; IN VITRO STUDY; INFECTION RISK; LYMPHOCYTE COUNT; LYMPHOCYTE FUNCTION; NATURAL KILLER CELL; PRIORITY JOURNAL; T CELL DEPLETION;

ADOLESCENT; ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTIBODIES, NEOPLASM; APOPTOSIS; CELL DEATH; CELL LINE, TUMOR; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KILLER CELLS, NATURAL; LYMPHOCYTE DEPLETION; MIDDLE AGED; TRANSPLANTATION, HOMOLOGOUS;

EID: 40249091629     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/sj.bmt.1705911     Document Type: Article

References (22)

1. Ferrara JL, Deeg HJ. Graft-versus-host disease. N Engl J Med 1991; 324: 667-674.
2. Kroger N, Shaw B, Iacobelli S, Zabelina T, Peggs K, Shimoni A et al Comparison between antithymocyte globulin and alemtuzumab and the possible impact of KIR-ligand mismatch after dose-reduced conditioning and unrelated stem cell transplantation in patients with multiple myeloma. Br J Haematol 2005; 129: 631-643.
3. Dodero A, Carrabba M, Milani R, Rizzo E, Raganato A, Montefusco V et al. Reduced-intensity conditioning containing low-dose alemtuzumab before allogeneic peripheral blood stem cell transplantation: graft-versus-host disease is decreased but T-cell reconstitution is delayed. Exp Hematol 2005; 33: 920-927.
4. Fehse N, Fehse B, Kroger N, Zabelina T, Freiberger P, Kruger W et al Influence of anti-thymocyte globulin as part of the conditioning regimen on immune reconstitution following matched related bone marrow transplantation. J Hematother Stem Cell Res 2003; 12: 237-242.
5. Giebel S, Dziaczkowska J, Wojnar J, Krawczyk-Kulis M, Markiewicz M, Kruzel T et al. The impact of immunosuppressive therapy on an early quantitative NK cell reconstitution after allogeneic haematopoietic cell transplantation. Ann Transplant 2005; 10 29-33.
6. Appelbaum FR. Haematopoietic cell transplantation as immunotherapy. Nature 2001; 411: 385-389.
7. Ruggeri L, Capanni M, Urbani E, Perruccio K, Shlomchik WD, Tosti A et al. Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science 2002; 295: 2097-2100.
8. Alter G, Malenfant JM, Altfeld M. CD107a as a functional marker for the identification of natural killer cell activity. J Immunol Methods 2004; 294: 15-22.
9. Penack O, Gentilini C, Fischer L, Asemissen AM, Scheibenbogen C, Thiel E et al. CD56dimCD16neg cells are responsible for natural cytotoxicity against tumor targets. Leukemia 2005; 19: 835-840.
10. Koopman G, Reutelingsperger CP, Kuijten GA, Keelmen RM, Pals ST, van Oers MH. Annexin V for flow cytometric detection of phosphatidylserine expression on B cells undergoing apoptosis. Blood 1994; 84: 1415-1420.
11. Vermes I, Haanen C, Steffens-Nakken H, Reutelingsperger C. A novel assay for apoptosis. Flow cytometric detection of phosphatidylserine expression on early apoptotic cells using fluorescein labelled Annexin V. J Immunol Methods 1995; 184: 39-51.
12. Gallagher R, Collins S, Trujillo J, McCredie K, Ahearn M, Tsai S et al. Characterization of the continuous, differentiating myeloid cell line (HL-60) from a patient with acute promyelocytic leukemia. Blood 1979; 54: 713-733.
13. Lozzio BB, Lozzio CB. Properties and usefulness of the original K-562 human myelogenous leukemia cell line. Leuk Res 1979; 3: 363-370.
14. Giebel S, Locatelli F, Lamparelli T, Velardi A, Davies S, Frumento G et al. Survival advantage with KIR ligand incompatibility in hematopoietic stem cell transplantation from unrelated donors. Blood 2003; 102: 814-819.
15. Hale G, Rebello P, Brettman LR, Fegan C, Kennedy B, Kimby E et al. Blood concentrations of alemtuzumab and antiglobulin responses in patients with chronic lymphocytic leukemia following intravenous or subcutaneous routes of administration. Blood 2004; 104: 948-955.
16. Rebello P, Cwynarski K, Varughese M, Eades A, Apperley JF, Hale G. Pharmacokinetics of CAMPATH-1H in BMT patients. Cytotherapy 2001; 3: 261-267.
17. Waller EK, Langston AA, Lonial S, Cherry J, Somani J, Allen AJ et al Pharmacokinetics and pharmacodynamics of antithymocyte globulin in recipients of partially HLA-matched blood hematopoietic progenitor cell transplantation. Biol Blood Marrow Transplant 2003; 9: 460-471.
18. Peleg AY, Husain S, Kwak EJ, Silveira FP, Ndirangu M, Tran J et al Opportunistic infections in 547 organ transplant recipients receiving alemtuzumab, a humanized monoclonal CD-52 antibody. Clin Infect Dis 2007; 44: 204-212.
19. Sandherr M, Einsele H, Hebart H, Kahl C, Kern W, Kiehl M et al. Antiviral prophylaxis in patients with haematological malignancies and solid tumours: Guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society for Hematology and Oncology (DGHO). Ann Oncol 2006; 17: 1051-1059.
20. Charbonnier A, Sainty D, Faucher C, Arnoulet C, Chabannon C, Blaise D. Immune reconstitution after blood cell transplantation. Hematol Cell Ther 1997; 39: 261-264.
21. Lowdell MW, Craston R, Ray N, Koh M, Galatowicz G, Prentice HG. The effect of T cell depletion with Campath-1M on immune reconstitution after chemotherapy and allogeneic bone marrow transplant as treatment for leukaemia. Bone Marrow Transplant 1998; 21: 679-686.
22. Ottinger HD, Beelen DW, Scheulen B, Schaefer UW, Grosse-Wilde H. Improved immune reconstitution after allotransplantation of peripheral blood stem cells instead of bone marrow. Blood 1996; 88: 2775-2779.